Every pregnant woman undergoes several blood tests during her pregnancy, which is an obstacle for hourly workers and underserved communities with limited access to healthcare. No-show rates for pregnancies of unknown location (PULs), including ectopic pregnancies, at Penn Medicine Dickens Clinic are about 25% alone; these women need remote quantitative tracking of beta-hCG. In 2023, urine-based pregnancy monitoring devices will influence 1.65 billion women worldwide. Serum-based tests are still the standard of care; community outreach programs are an existing solution, but these do not address fundamental issues with access to diagnostic centers.
Proposed Healthcare Solution
Urine-based device that replaces blood tests needed during pregnancy
Ankita Brahmaroutu, MD
Department of Neurology
Efe Cudjoe, MD
Department of Obstetrics and Gynecology
Perelman School of Medicine